Fidelity Investments’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Fidelity Investments’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-674,800	Closed	-$6.87M	–	4462
2020 Q3	$6.87M	Sell	674,800 -67,200	-9%	-$902K	﹤0.01%	1960
2020 Q2	$11.1M	Sell	742,000 -46,600	-6%	-$718K	﹤0.01%	1782
2020 Q1	$9.61M	Sell	788,600 -83,400	-10%	-$1.33M	﹤0.01%	1703
2019 Q4	$13.8M	Hold	872,000	–	–	﹤0.01%	1733
2019 Q3	$10.7M	Buy	872,000 +55,000	+7%	+$623K	﹤0.01%	1800
2019 Q2	$10.8M	Buy	+817,000	New	+$11.9M	﹤0.01%	1853

Other funds holding PRVL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments's PRVL Position: Q4 2020 in Review

Fidelity Investments sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q4 2020, closing a stake of 674,800 shares — an estimated $6.87M sold.

Fidelity Investments first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $13.8M in Q4 2019. 93 funds tracked by Wall St. Rank hold PRVL as of Q4 2020.

Fidelity Investments reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Fidelity Investments sold 674,800 Prevail Therapeutics Inc. Common Stock shares in Q4 2020, an estimated $6.87M.
Fidelity Investments first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 6 quarters.
Fidelity Investments's Prevail Therapeutics Inc. Common Stock position peaked at $13.8M in Q4 2019.
93 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q4 2020.

Based on Fidelity Investments's 13F filing for Q4 2020, filed 8 Feb 2021.